AFT announces $10m capital raise plus share sell down
Company founder is selling some of his stake but intends to remain the largest shareholder.
Dual-listed AFT Pharmaceuticals announced a $10 million capital raise to the NZX today along with a major share selloff.
The surplus cashflow will be used to target a net debt of between $23m and $28m. The company has entered into a trading halt.
Founder and managing director Dr Hartley
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
